# Reference List

Kostadin Kostadinov

## References

[1] Nicolas Garnier et al. “Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe”. en. In: *PLOS ONE* 18.11 (Nov. 2023), e0293503. ISSN: 1932-6203. DOI: 10.1371/journal.pone.0293503. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293503.

[2] Kaloyan Guevara and Kostadin Kostadinov. “Neurological Soft Signs and Social Cognition in Patients with Schizophrenia: the Missing Link”. In: *Proceedings of the Bulgarian Academy of Sciences* 76.9 (Oct. 2023), pp. 1440–1448. DOI: 10.7546/CRABS.2023.09.15. URL: https://www.proceedings.bas.bg/index.php/cr/article/view/391.

[3] M. Hubenova and K. Kostadinov. “Change in eating habits during the COVID-19 confinement”. In: *General Medicine* 24.1 (2022), pp. 23–29. URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131335656&partnerID=40&md5=960321f2fcf677479ecd9d43d8f6d6d0.

[4] Valentina Ignatova et al. “Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria”. In: *Front. Public Health* 10 (Mar. 2022). DOI: 10.3389/fpubh.2022.822909. URL: https://doi.org/10.3389%2Ffpubh.2022.822909.

[5] Georgi Iskrov et al. “Are the European reference networks for rare diseases ready to embrace machine learning? A mixed-methods study”. In: *Orphanet Journal of Rare Diseases* 19.1 (Jan. 2024), p. 25. ISSN: 1750-1172. DOI: 10.1186/s13023-024-03047-7. URL: https://doi.org/10.1186/s13023-024-03047-7.

[6] Peter Kelly et al. “Trauma Informed Interventions to Reduce Seclusion, Restraint and Restrictive Practices Amongst Staff Caring for Children and Adolescents with Challenging Behaviours: A Systematic Review”. In: *Journal of Child and Adolescent Trauma* (Mar. 2023). ISSN: 1936-153X. DOI: 10.1007/s40653-023-00524-2. URL: http://dx.doi.org/10.1007/s40653-023-00524-2.

[7] Faik Kiani et al. “Dentophobia-latent Component Factor Analysis of Dental Concerns Assessment Scale”. In: *Open Access Maced J Med Sci* 11.E (Jan. 2023), pp. 53–58. DOI: 10.3889/oamjms.2023.9749. URL: https://doi.org/10.3889%2Foamjms.2023.9749.

[8] Kostadin Kostadinov and Nina Musurlieva. “Historical Overview of the Definition of Rare Tumors in the Context of Health Policies”. bg. In: *Rare Diseases and Orphan Drugs Journal* 14.2 (Nov. 2023), pp. 6–12. ISSN: 1314-3581. DOI: 10.36865/2023.v14i2.182. URL: https://journal.raredis.org/index.php/RBLS/article/view/182.

[9] Kostadin Kostadinov et al. “Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures”. en. In: *Cancers* 16.8 (Apr. 2024), p. 1489. ISSN: 2072-6694. DOI: 10.3390/cancers16081489. URL: https://www.mdpi.com/2072-6694/16/8/1489.

[10] Kostadin Kostadinov et al. “Epidemiology of Acquired Thrombotic Thrombocytopenic Purpura”. In: *Rare Diseases and Orphan Drugs* 11.3 (Oct. 2020), pp. 36–44. ISSN: 1314-3581. DOI: 10.36865/2020.v11i3.122. URL: https://journal.raredis.org/index.php/RBLS/article/view/122.

[11] R Raycheva and K Kostadinov. “HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria”. In: *Value in Health* 25.12 (Dec. 2022), S309–S310. ISSN: 1098-3015. DOI: 10.1016/j.jval.2022.09.1529. URL: http://dx.doi.org/10.1016/j.jval.2022.09.1529.

[12] R. Raycheva and K. Kostadinov. “HTA7 The Price of Innovation – Oncology Treatments Expenditures: Case from Bulgaria”. en. In: *Value in Health* 26.6 (June 2023), S260. ISSN: 10983015. DOI: 10.1016/j.jval.2023.03.1436. URL: https://linkinghub.elsevier.com/retrieve/pii/S109830152301536X.

[13] Ralitsa Raycheva et al. “Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review”. In: *Frontiers in Public Health* 11 (2023). ISSN: 2296-2565. DOI: 10.3389/fpubh.2023.1214766. URL: https://www.frontiersin.org/articles/10.3389/fpubh.2023.1214766.

[14] Ralitsa Raycheva et al. “Landscape analysis of available European data sources amenable for machine learning and recommendations on usability for rare diseases screening”. en. In: *Orphanet Journal of Rare Diseases* 19.1 (Apr. 2024), p. 147. ISSN: 1750-1172. DOI: 10.1186/s13023-024-03162-5. URL: https://doi.org/10.1186/s13023-024-03162-5.

[15] Editor RBLS. “6th National Conference on Rare Diseases and Orphan Drugs - Abstract Collection”. In: *Rare Diseases and Orphan Drugs Journal* 6.1 (Nov. 2019). ISSN: 1314-3581. DOI: 10.36865/2015.v6i1.92. URL: http://journal.raredis.org/index.php/RBLS/article/view/92.